CA2906796A1 - Transdermal drug delivery system containing rivastigmine - Google Patents

Transdermal drug delivery system containing rivastigmine

Info

Publication number
CA2906796A1
CA2906796A1 CA2906796A CA2906796A CA2906796A1 CA 2906796 A1 CA2906796 A1 CA 2906796A1 CA 2906796 A CA2906796 A CA 2906796A CA 2906796 A CA2906796 A CA 2906796A CA 2906796 A1 CA2906796 A1 CA 2906796A1
Authority
CA
Canada
Prior art keywords
delivery system
drug delivery
transdermal drug
none none
acrylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2906796A
Other languages
English (en)
French (fr)
Inventor
Je Phil Ryoo
Y. Joseph Mo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nal Pharmaceutical Group Ltd
Original Assignee
Nal Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nal Pharmaceuticals Ltd filed Critical Nal Pharmaceuticals Ltd
Publication of CA2906796A1 publication Critical patent/CA2906796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
CA2906796A 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine Abandoned CA2906796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799015P 2013-03-15 2013-03-15
US61/799,015 2013-03-15
PCT/US2014/027357 WO2014152454A1 (en) 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine

Publications (1)

Publication Number Publication Date
CA2906796A1 true CA2906796A1 (en) 2014-09-25

Family

ID=51528077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906796A Abandoned CA2906796A1 (en) 2013-03-15 2014-03-14 Transdermal drug delivery system containing rivastigmine

Country Status (10)

Country Link
US (1) US20140271866A1 (https=)
EP (1) EP2968248A4 (https=)
JP (1) JP6391664B2 (https=)
KR (1) KR20160005024A (https=)
CN (1) CN105263488A (https=)
AU (1) AU2014239687B2 (https=)
CA (1) CA2906796A1 (https=)
HK (1) HK1220109A1 (https=)
TW (1) TWI635876B (https=)
WO (1) WO2014152454A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104523656A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 一种卡巴拉汀缓释透皮贴剂及其制备方法
CN105693556A (zh) * 2016-03-01 2016-06-22 巴斯特医药科技（常州）有限公司 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
US11389421B2 (en) 2017-09-05 2022-07-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of rivastigmine
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
KR102710072B1 (ko) * 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
CN108926549A (zh) * 2018-09-27 2018-12-04 安徽安科余良卿药业有限公司 卡巴拉汀凝胶贴膏及其制备方法
TWI720366B (zh) 2018-11-16 2021-03-01 得生製藥股份有限公司 經皮吸收貼片
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
KR960703956A (ko) * 1993-07-08 1996-08-31 로버트 지. 반 슌넨베르그 아크릴릭-포화 고무 하이브리드 감압 접착제
DE19918106A1 (de) * 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US20020192243A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
US6455066B1 (en) * 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US7516422B2 (en) * 2005-07-21 2009-04-07 International Business Machines Corporation Graphical display of hierarchical hardlinks to files in a file system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE602006020063D1 (de) * 2005-12-07 2011-03-24 Univ Ramot Wirkstoffabgebende verbundkörper
WO2009158032A1 (en) * 2008-06-25 2009-12-30 Fe2, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
US8440304B2 (en) * 2008-09-16 2013-05-14 Henkel Corporation Acrylic pressure sensitive adhesive formulation and articles comprising same
CN102630160B (zh) * 2009-09-16 2014-05-07 株式会社三养生物制药 透皮递送系统、其制备方法以及使用所述系统的透皮递送方法
JP2012236773A (ja) * 2009-12-16 2012-12-06 Goto Takeshi 抗認知症薬物の経皮吸収製剤
NZ605352A (en) * 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
DE102010026903A1 (de) * 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
KR101853082B1 (ko) * 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물

Also Published As

Publication number Publication date
AU2014239687A1 (en) 2015-10-08
EP2968248A4 (en) 2016-08-31
HK1220109A1 (zh) 2017-04-28
TWI635876B (zh) 2018-09-21
EP2968248A1 (en) 2016-01-20
WO2014152454A1 (en) 2014-09-25
JP6391664B2 (ja) 2018-09-19
TW201505665A (zh) 2015-02-16
KR20160005024A (ko) 2016-01-13
CN105263488A (zh) 2016-01-20
AU2014239687B2 (en) 2018-04-05
US20140271866A1 (en) 2014-09-18
JP2016522792A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
AU2014239687B2 (en) Transdermal drug delivery system containing rivastigmine
DK2515886T3 (en) Transdermal therapeutic system for administration of rivastigmine or derivatives thereof
JP5913981B2 (ja) ドネペジル含有経皮吸収型製剤
KR101192969B1 (ko) 도네페질을 함유하는 경피흡수제제
AU2014276910B2 (en) Transdermal delivery system
JP6043296B2 (ja) 有効成分を投与するための経皮治療システム
CZ307857B6 (cs) Transdermální náplast pro podávání fentanylu nebo jeho analogu
KR20120107153A (ko) 펜타닐 경피 패치제
CN103313705A (zh) 含有利凡斯的明的经皮吸收制剂
JP2015502940A (ja) フェンタニルまたはその類似体の投与のための経皮治療システム
TW201811318A (zh) 一種包含葛蘭他命或其醫藥用鹽類的穿皮釋放系統
WO2013047410A1 (ja) 持続型アルツハイマー病治療用貼付剤及びその製造方法
JP5632577B2 (ja) 貼付剤
US10076502B2 (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
US20140370077A1 (en) Transdermal drug delivery system containing fentanyl
JP7402829B2 (ja) リバスチグミンを含有する経皮治療システム
HK40050766A (en) Transdermal therapeutic system containing rivastigmine
WO2014159778A1 (en) Transdermal drug delivery system containing fentanyl
OA17599A (en) Transdermal delivery system
KR20150064842A (ko) 케토티펜 또는 그 염을 함유하는 경피흡수제제

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190207

FZDE Discontinued

Effective date: 20211116